Osteonecrose dos maxilares associados a medicamentos (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Osteonecrose dos maxilares associados a medicamentos" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

15nih.gov

4^th place

8^th place

9doi.org

2^nd place

4^th place

1bjorl.org.br

low place

1elsevier.com

610^th place

360^th place

1joms.org

low place

1sdcep.org.uk

low place

1jcbarbi.com.br

low place

bjorl.org.br

Kemp, Aristilia; Ferreira, Vitor; Mobile, Rafael; et al. «Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients». Brazilian Journal of Otorhinolaryngology. doi:10.1016/j.bjorl.2020.09.010. Consultado em 10 de janeiro de 2021. Cópia arquivada em Novembro de 2020

doi.org

dx.doi.org

Kemp, Aristilia; Ferreira, Vitor; Mobile, Rafael; et al. «Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients». Brazilian Journal of Otorhinolaryngology. doi:10.1016/j.bjorl.2020.09.010. Consultado em 10 de janeiro de 2021. Cópia arquivada em Novembro de 2020
Thumbigere-Math, Vivek; Tu, Lam; Huckabay, Sabrina; et al. (Agosto de 2012). «A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates». American Journal of Clinical Oncology. 35 (4): 386–92. PMID 22561331. doi:10.1097/COC.0b013e3182155fcb. Consultado em 10 de janeiro de 2021
Nase, John B; Suzuki, Jon B (Agosto de 2006). «Osteonecrosis of the jaw and oral bisphosphonate treatment». Journal of the American Dental Association. 137 (8): 1115–9; quiz 1169–70. PMID 16873327. doi:10.14219/jada.archive.2006.0350. Consultado em 10 de janeiro de 2021
Marx RE (Setembro de 2003). «Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic». Journal of Oral and Maxillofacial Surgery. 61 (9): 1115–7. PMID 12966493. doi:10.1016/s0278-2391(03)00720-1
Migliorati CA (Novembro de 2003). «Bisphosphanates and oral cavity avascular bone necrosis». Journal of Clinical Oncology. 21 (22): 4253–4. PMID 14615459. doi:10.1200/JCO.2003.99.132
Ruggiero SL; Dodson TB; Fantasia J; et. al (Outubro de 2014). «American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update». Journal of Oral and Maxillofacial Surgery. 72 (10): 1938–56. PMID 25234529. doi:10.1016/j.joms.2014.04.031
Sigua-Rodriguez EA; da Costa Ribeiro R; de Brito AC; Alvarez-Pinzon N; de Albergaria-Barbosa JR (Abril de 2014). «Bisphosphonate-related osteonecrosis of the jaw: a review of the literature». International Journal of Dentistry. 2014. 192320 páginas. PMC 4020455. PMID 24868206. doi:10.1155/2014/192320
Ruggiero, Salvatore L. (Fevereiro de 2013). «Emerging concepts in the management and treatment of osteonecrosis of the jaw». Oral and Maxillofacial Surgery Clinics of North America. 25 (1): 11–20. PMID 23159218. doi:10.1016/j.coms.2012.10.002. Consultado em 9 de janeiro de 2021
Hellstein, John W; Adler, Robert A; Edwards, Beatrice; et al. (Novembro de 2011). «Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs». Journal of the American Dental Association. 142 (11): 1243–51. PMID 22041409. doi:10.14219/jada.archive.2011.0108. Consultado em 9 de janeiro de 2021

elsevier.com

reader.elsevier.com

Kemp, Aristilia; Ferreira, Vitor; Mobile, Rafael; et al. «Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients». Brazilian Journal of Otorhinolaryngology. doi:10.1016/j.bjorl.2020.09.010. Consultado em 10 de janeiro de 2021. Cópia arquivada em Novembro de 2020

jcbarbi.com.br

«Fratura Patológica». jcbarbi.com. 23 de dezembro de 2019. Consultado em 6 de fevereiro de 2022

joms.org

Marx RE (Setembro de 2003). «Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic». Journal of Oral and Maxillofacial Surgery. 61 (9): 1115–7. PMID 12966493. doi:10.1016/s0278-2391(03)00720-1

nih.gov

ncbi.nlm.nih.gov

Thumbigere-Math, Vivek; Tu, Lam; Huckabay, Sabrina; et al. (Agosto de 2012). «A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates». American Journal of Clinical Oncology. 35 (4): 386–92. PMID 22561331. doi:10.1097/COC.0b013e3182155fcb. Consultado em 10 de janeiro de 2021
Nase, John B; Suzuki, Jon B (Agosto de 2006). «Osteonecrosis of the jaw and oral bisphosphonate treatment». Journal of the American Dental Association. 137 (8): 1115–9; quiz 1169–70. PMID 16873327. doi:10.14219/jada.archive.2006.0350. Consultado em 10 de janeiro de 2021
Marx RE (Setembro de 2003). «Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic». Journal of Oral and Maxillofacial Surgery. 61 (9): 1115–7. PMID 12966493. doi:10.1016/s0278-2391(03)00720-1
Migliorati CA (Novembro de 2003). «Bisphosphanates and oral cavity avascular bone necrosis». Journal of Clinical Oncology. 21 (22): 4253–4. PMID 14615459. doi:10.1200/JCO.2003.99.132
Ruggiero SL; Dodson TB; Fantasia J; et. al (Outubro de 2014). «American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update». Journal of Oral and Maxillofacial Surgery. 72 (10): 1938–56. PMID 25234529. doi:10.1016/j.joms.2014.04.031
Sigua-Rodriguez EA; da Costa Ribeiro R; de Brito AC; Alvarez-Pinzon N; de Albergaria-Barbosa JR (Abril de 2014). «Bisphosphonate-related osteonecrosis of the jaw: a review of the literature». International Journal of Dentistry. 2014. 192320 páginas. PMC 4020455. PMID 24868206. doi:10.1155/2014/192320
Ruggiero, Salvatore L. (Fevereiro de 2013). «Emerging concepts in the management and treatment of osteonecrosis of the jaw». Oral and Maxillofacial Surgery Clinics of North America. 25 (1): 11–20. PMID 23159218. doi:10.1016/j.coms.2012.10.002. Consultado em 9 de janeiro de 2021
Hellstein, John W; Adler, Robert A; Edwards, Beatrice; et al. (Novembro de 2011). «Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs». Journal of the American Dental Association. 142 (11): 1243–51. PMID 22041409. doi:10.14219/jada.archive.2011.0108. Consultado em 9 de janeiro de 2021
«Table 6. ONJ Staging System». PDQ Supportive and Palliative Care Editorial Board, National Center for Biotechnology Information, U.S. National Library of Medicine. 16 de dezembro de 2016. Consultado em 6 de fevereiro de 2022 Este artigo incorpora texto desta fonte, que está no domínio público.

pubmed.ncbi.nlm.nih.gov

Thumbigere-Math, Vivek; Tu, Lam; Huckabay, Sabrina; et al. (Agosto de 2012). «A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates». American Journal of Clinical Oncology. 35 (4): 386–92. PMID 22561331. doi:10.1097/COC.0b013e3182155fcb. Consultado em 10 de janeiro de 2021
Nase, John B; Suzuki, Jon B (Agosto de 2006). «Osteonecrosis of the jaw and oral bisphosphonate treatment». Journal of the American Dental Association. 137 (8): 1115–9; quiz 1169–70. PMID 16873327. doi:10.14219/jada.archive.2006.0350. Consultado em 10 de janeiro de 2021
Migliorati CA (Novembro de 2003). «Bisphosphanates and oral cavity avascular bone necrosis». Journal of Clinical Oncology. 21 (22): 4253–4. PMID 14615459. doi:10.1200/JCO.2003.99.132
Ruggiero SL; Dodson TB; Fantasia J; et. al (Outubro de 2014). «American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update». Journal of Oral and Maxillofacial Surgery. 72 (10): 1938–56. PMID 25234529. doi:10.1016/j.joms.2014.04.031
Ruggiero, Salvatore L. (Fevereiro de 2013). «Emerging concepts in the management and treatment of osteonecrosis of the jaw». Oral and Maxillofacial Surgery Clinics of North America. 25 (1): 11–20. PMID 23159218. doi:10.1016/j.coms.2012.10.002. Consultado em 9 de janeiro de 2021
Hellstein, John W; Adler, Robert A; Edwards, Beatrice; et al. (Novembro de 2011). «Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs». Journal of the American Dental Association. 142 (11): 1243–51. PMID 22041409. doi:10.14219/jada.archive.2011.0108. Consultado em 9 de janeiro de 2021

sdcep.org.uk

«Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw» (PDF). Scottish Dental Clinical Effectiveness Programme. Março de 2017